Arbutus Biopharma (LTS:0SGC) Accumulated Depreciation : $-13.33 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Arbutus Biopharma Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Arbutus Biopharma's quarterly accumulated depreciation increased from Sep. 2024 ($-12.66 Mil) to Dec. 2024 ($-13.00 Mil) and increased from Dec. 2024 ($-13.00 Mil) to Mar. 2025 ($-13.33 Mil).

Arbutus Biopharma's annual accumulated depreciation increased from Dec. 2022 ($-10.80 Mil) to Dec. 2023 ($-11.90 Mil) and increased from Dec. 2023 ($-11.90 Mil) to Dec. 2024 ($-13.00 Mil).

Arbutus Biopharma Accumulated Depreciation Historical Data

The historical data trend for Arbutus Biopharma's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Accumulated Depreciation Chart

Arbutus Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-7.62

-9.37

-10.80

-11.90

-13.00

Arbutus Biopharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated Depreciation	Get a 7-Day Free Trial															-12.26	-12.61	-12.66	-13.00	-13.33

Arbutus Biopharma Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Arbutus Biopharma Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (LTS:0SGC) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

ABUS:USA I9DN:Germany I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Headlines

No Headlines